PlumX Metrics
Embed PlumX Metrics

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

Pharmacogenomics Journal, ISSN: 1470-269X, Vol: 9, Issue: 5, Page: 347-353
2009
  • 115
    Citations
  • 0
    Usage
  • 72
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Platinum agents cause DNA cross-linking. Nucleotide excision repair genes play a key role in DNA damage repair. This study aims to investigate whether polymorphisms in these genes are associated with tumor response and survival in cisplatin-treated osteosarcoma patients. Eight single nucleotide polymorphisms in ERCC2, XPC, XPA, ERCC1, ERCC4 and ERCC5 genes were analyzed in 91 patients diagnosed with osteosarcoma and treated with cisplatin. A significant association with tumor response, after correction for multiple testing, was found for the Lys751Gln polymorphism in the ERCC2 gene. We found that only 45% of patients with at least one polymorphic G allele responded compared with 80% of patients homozygous for the common T allele (odds ratio = 4.9, 95% confidence interval = 1.64-14.54, adjusted P-value = 0.047). In addition, carrying at least one ERCC2 Lys751GlnG allele was significantly associated with shorter event-free survival (median = 84 months, compared with 240 months for T T homozygotes; hazard ratio = 5.76, 95% confidence interva = 1.30-25.55; P-value = 0.021). Although ototoxicity was only recorded in 32 patients, we found weak evidence of an association with the CC genotype of XPC Lys939Gln (P-value = 0.042). This is the first pharmacogenetic study focused on osteosarcoma treatment providing evidence that polymorphic variants in DNA repair genes could be useful predictors of response to cisplatin chemotherapy in osteosarcoma patients.

Bibliographic Details

D. Caronia; R. L. Milne; G. Pita; M. R. Alonso; L. T. Moreno; J. Benítez; A. Gonzáles-Neira; A. Patiño-García; M. Zalacain-Díez; L. Sierrasesumaga-Ariznabarreta

Springer Science and Business Media LLC

Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know